Cargando…

Ferritin level changes and erythroid improvement in a group of adult polytransfused patients treated with Deferasirox

BACKGROUND AND AIMS: Chelating agents therapy is recommended for polytransfused patients that have evidence of iron overload (an elevated serum ferritin or received over 20 units of red blood cell transfusions). Deferasirox showed efficacy and safety in maintaining or reducing body iron. Iron chelat...

Descripción completa

Detalles Bibliográficos
Autores principales:	PARVU, ANDRADA VIORICA, BOJAN, ANCA, URIAN, LAURA, TOROK, TUNDE, ZSOLDOS, IULIA ANDREA, IANCU, MIHAELA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iuliu Hatieganu University of Medicine and Pharmacy 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082613/ https://www.ncbi.nlm.nih.gov/pubmed/30093806 http://dx.doi.org/10.15386/cjmed-942

Ejemplares similares

Macrophage activation syndrome: A diagnostic challenge (Review)
por: Bojan, Anca, et al.
Publicado: (2021)

Assessment and Management of Cardiotoxicity in Hematologic Malignancies
por: Bojan, Anca, et al.
Publicado: (2021)

A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience
por: Jimbu, Laura, et al.
Publicado: (2023)

Comparative metavirome analysis in polytransfused patients
por: Valença, I.N., et al.
Publicado: (2021)

Primary non-Hodgkin lymphoma of the orbit presenting with massive bilateral periorbital tumors
por: TŐRŐK-VISTAI, TÜNDE, et al.
Publicado: (2013)

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
por: Meunier, Mathieu, et al.
Publicado: (2017)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Retrospective Analysis of Endocrine Dysfunctions in a Population of Adult Polytransfused Patients: Correlation of GH-IGF1 Axis Alteration with Cardiac Performance
por: Campo, Michela Rosaria, et al.
Publicado: (2018)

Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox
por: Ghazanfari, Azam, et al.
Publicado: (2019)

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
por: Porter, John B, et al.
Publicado: (2011)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox
por: Lescano, Manuel A, et al.
Publicado: (2017)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging
por: Seldrum, Stéphanie, et al.
Publicado: (2011)

Allo-immunisation anti-érythrocytaire chez les polytransfusés au Centre National Hospitalier Universitaire de Cotonou: à propos de 51 cas
por: Baglo, Tatiana, et al.
Publicado: (2021)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Deferasirox – a rarer cause of Fanconi syndrome
por: Khan, Iman, et al.
Publicado: (2019)

Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
por: Gascon, Jose Miguel, et al.
Publicado: (2019)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

A Real-Life Action toward the End of HIV Pandemic: Surveillance of Mother-to-Child HIV Transmission in a Center from Southeast Romania
por: Arbune, Manuela, et al.
Publicado: (2022)

H-Ferritin Is Preferentially Incorporated by Human Erythroid Cells through Transferrin Receptor 1 in a Threshold-Dependent Manner
por: Sakamoto, Soichiro, et al.
Publicado: (2015)

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
por: Saigo, Katsuyasu, et al.
Publicado: (2013)

Deferasirox: appraisal of safety and efficacy in long-term therapy
por: Chaudhary, Preeti, et al.
Publicado: (2013)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring
por: Piolatto, Andrea, et al.
Publicado: (2021)

Effects of Deferasirox in Alzheimer’s Disease and Tauopathy Animal Models
por: Kwan, Ping, et al.
Publicado: (2022)

Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery
por: Faizi, Hafsa Shahid, et al.
Publicado: (2022)

Evolution of ferritin levels in hepatitis C patients treated with antivirals
por: Chang, Ming-Ling, et al.
Publicado: (2020)

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
por: Tartaglione, Immacolata, et al.
Publicado: (2020)

Deferasirox in Indian children with thalassemia major: 3 years experience
por: Dhamija, Mayank, et al.
Publicado: (2013)

The potential of deferasirox as a novel therapeutic modality in gastric cancer
por: Choi, Jung Hye, et al.
Publicado: (2016)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

Perforated duodenal ulcer: A rare complication of deferasirox in children
por: Yadav, Sunil Kumar, et al.
Publicado: (2013)

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome
por: Polat, Asude Kara, et al.
Publicado: (2017)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
por: Rodríguez-García, Alba, et al.
Publicado: (2019)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ppbb99ud9mqo8hbvqgroe3mff7